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Abstract
The Familial Mediterranean fever (FMF, MIM249100) is an autoimflammatory genetic disease characterized with recurrent painful 
attacks in the abdomen, chest or joints, usually accompanied with high body temperature. It is classically inherited in an autosomal reces-
sive manner. It is associated with mutations of the MEFV gene, coding for the protein pyrin. More than 140 mutations of the MEFV gene 
are defined worldwide. Despite the progress in establishing reliable tests practical for routine use, as much as 20% of the patients with FMF 
remain without a detectable mutation in the MEFV gene. This is the main reason why the diagnosis of FMF remains still a clinical one, ac-
cording to Tel Hashomer criteria.
A 10-year old girl admitted to the Clinic of Pediatrics at the Faculty of Medicine in Skopje for unexplained fever. After numerous lab-
oratory analyses and specialist consultations were done, genetic testing for FMF was requested. The presence of an heterozygous mutation 
E148Q was confirmed at the Institute for Immunobiology and Human Genetics using a PCR based, reverse hybridization method. Admin-
istration of colchicine, the therapy of choice, in a dose of 1.5 mg/day, lead to complete resolution of the symptoms within some days fol-
lowing commencement.
Although the disease is classically inherited in a recessive manner, some atypical cases of autosomal dominant inheritance are 
described. Our patient may be another example supporting the unusual dominant inheritance, since the heterozygous state for the E148Q 
mutation was the only positive finding in the genotyping of the 12 most frequent MEFV mutations. 
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Introduction
Familial Mediterranean fever (FMF, MIM249100) is 
a genetic multi-systemic disease with recurrent painful at-
tacks in the abdomen, chest or joints as a main character-
istic. Usually, the attacks are accompanied by high body 
temperature, and sometimes a skin rush. The disease was 
recognized as a separate entity in 1945 (Bakkaloglu, 2003). 
Today, it is known under many names, such as recurrent 
hereditary polyserositis, benign paroxysmal peritonitis, 
periodical fever, periodical amyloid syndrome, Armenian 
syndrome or Reimann’s periodical disease (Ben-Chetrit 
et al., 1998; Booth et al., 2000; Brik et al., 2001; Caze-
neuve et al., 1999; Ryan et al., 2010). Most frequently, this 
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disease is found in people originating from the Mediterra-
nean region (therefore the name), and classically it is most 
prevalent in four populations: Sephardi Jews (1/250-1000), 
Armenians (1/500), Turks (1/1000) and Arabs (1/2600). 
(Booth et al., 2000; Brik et al., 2001; Cazeneuve et al., 
2000; Fujikura et al., 2015). It is significantly less frequent 
in other populations. A vast number of patients with FMF 
(80-95%) are younger than 20 years at the time of diagno-
sis, while 50-60% of them are younger than 10 years (De-
walle et al., 1998; El-Shanti 2001). Main complications 
associated with this disease are destructive oligoarthritis 
and secondary amyloidosis which could potentially lead to 
death (Gedalia 2004; Gershoni-Baruch et al., 2003; Ger-
shoni-Baruch et al., 2002; Gershoni-Baruch et al., 2001).
The disease is classically inherited in an autosomal re-
cessive manner. After identification of the gene responsi-
ble for the disease MEFV, in 1997, numerous studies have 
been conducted in order to examine the distribution of dif-
ferent MEFV mutations across populations and the differ-
ent genotype- phenotype correlation (Brik et al., 2001; Ca-
zeneuve et al., 2000; Gershoni-Baruch et al., 2001; Kishi-
da et al., 2014). The MEFV gene is located on chromosome 
13.3, and codes for a protein called pyrin or marenostrin, 
expressed only in neutrophils, serosal cells in the peritone-
al and pleural spaces and in synovial cells (Haghighat et 
al., 2006; Kastner 1998). The exact role of the protein is 
not yet known, but it was shown that it has certain effect 
on the control of the inflammation, probably through inhi-
bition of C5a and Il-8 (Kubik et al., 2006).
Case presentation
A 10 year old girl admitted to the Clinic of Pediatrics 
at the Faculty of Medicine in Skopje sub febrile, with sta-
ble vital parameters, pain in the left leg and discrete ede-
ma of the leg joints, accompanied with urticarial-like rash 
of the extremities. During her 13-day stay at the Clinic, re-
peated temperature rising up to 41 °C accompanied with 
fever and rash accentuation. Numerous laboratory tests 
and consultations with specialists were conducted. In ab-
sence of other obvious explanation for the fever, testing for 
FMF was requested. Presence of a heterozygous mutation 
E148Q was confirmed by genetic test.; the same detection 
was noted following father’s DNA examination. The de-
tection of the 12 most common MEFV mutations was per-
formed using the commercial FMF StripA kit (ViennaL-
Table 1. Tel Hashomer criteria for diagnosis of Familial Mediterranean Fever (FMF)*
Major criteria Minor criteria Supportive criteria
Typical attacks
•	 Peritonitis (generalized)
•	 Unilateral pleuritis or peri-
carditis
•	 Monoarthritis (hip, knee, 
ankle)
Incomplete attacks in one or 




•	 Exertional leg pain
•	 Positive response to colhicine
•	 Family history of FMF
•	 Adequate ethnic origin
•	 Age ≤20 at disease onset
•	 Severe attack 
•	 Spontaneous remission
•	 Period without symptoms
•	 Transient inflammatory response supported with >1 ab-
normal result of white blood cell count, erythrocyte sed-
imentation rate, serum amyloid A.
•	  Episodic proteinuria
•	 Consanguinity of parents
* For diagnosing of FMF are required: 
≥1 major criteria, or ≥2 minor criteria, or 
1 minor and ≥5 supportive criteria, or 
1 minor and ≥4 of the first 5 supportive criteria.
Typical attacks are defined attacks of pain which last shortly (between 12 hours and 3 days), are recurrent (≥3 of same type) 
and accompanied with high body temperature (rectal temperature ≥38°C).
Incomplete attacks are defined attacks of pain similar to typical, except: 
•	 Body temperature is not elevated; or
•	 Attacks last longer or shorter compared to typical; 
•	 During the abdominal painful attacks, there is no sign of peritonitis. 
•	 Abdominal attacks are localized;
•	 The arthritis is localized in atypical joints.
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ab, VIenna, Austria), based on PCR and reverse hybridiza-
tion technique. An informed consent was given prior to ex-
amination.
Management and outcome
According to the Tel Hashomer criteria (Table 1) (one 
major – monoarthritis, one minor – positive response to 
Colchicine, and five additional – age ≤ 20, severe attack, 
spontaneous remission, attack-free period, and occasion-
al inflammatory episodes with abnormal (high) leukocyte 
count and/or ESR), a diagnosis of FMF was assigned. The 
therapy of choice, colchicine, was prescribed orally in a 
dose of 1.5 mg/day, which lead to complete resolution of 
the symptoms following two days of treatment.
Discussion
In reviewing the spectrum and the penetrance of differ-
ent mutations of the MEFV gene, it seems that three muta-
tion hotspots are identified, namely codons 148, 680, and 
694. A total of more than 140 mutations of the MEFV gene 
are by now reported worldwide (Matzner et al., 1984). 
However, it is evident only five of them are globally re-
sponsible for the majority (some 70%) of the FMF cas-
es, namely mutations V726A, M694V, M694I, M680I and 
E148Q (Matzner et al., 1984; Pras et al., 1998; Mijatovic 
et al., 2003, Mohammadnejad, 2013). Despite the obvi-
ous progress in the last decade in establishing molecular 
tests convenient for routine use, as much as 20% of the pa-
tients with FMF remain without a detectable mutation in 
the MEFV gene and the diagnosis still relies on clinical cri-
teria. Another important characteristic of the disease is the 
diversity of symptoms and their varying severity in differ-
ent patients. Notably, this high heterogeneity is not always 
in parallel with the type of the mutation, although some 
mutations are believed to confer a more severe presenta-
tion (726, 694) whereas some other a less severe one (148) 
i.e. the clinical presentation of certain genotypes in homo-
zygous, heterozygous or combined heterozygous patients 
(Jéruet al 2013; Shohat et al., 1999; Shinawi et al., 2000; 
Tchernitchko et al., 2003 Touitu, 2001). This points out to 
potential modifying factors, such as gender, MEFV and 
other modifying mutations. Obviously, other, not yet iden-
tified population factors that influence the clinical manifes-
tation of the disease cannot be excluded. 
Although the disease is classically inherited in a re-
cessive manner, some atypical cases of autosomal domi-
nant inheritance are described. This finding was confirmed 
in two separate families, one with Ashkenazi, and the oth-
er with Georgian origin. By following the FMF in 4 suc-
cessive generations of family members, it was confirmed 
that in both cases the underlying mutation responsible for 
the unusual inheritance was E148Q (OMIM 607108.0005), 
present in heterozygous state. Again however, the role of 
other not as-yet identified pyrin gene mutations cannot be 
excluded.
Our patient may be another case supporting the un-
usual dominant inheritance, since the heterozygous state 
for the E148Q mutation was the only positive finding in 
the genotyping of the 12 most frequent MEFV mutations. 
It would be interesting to perform DNA sequencing of the 
entire MEFV gene in this patient (we are currently arrang-
ing it), in order to exclude possibly present genetic devia-
tions other than the twelve mutations analyzed. 
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Резиме
Приказ на случај со доминантно наследена фамилијарна 
медитеранска треска од Република Македонија
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Клучни зборови: Фамилијарна медитеранска треска, генетско тестирање, MEFVE148Q.
Фамилијарна медитеранска треска (ФМФ, MIM249100) е автоинфламаторнагенетска болест која се карактеризира 
со повторливи болни напади во пределот на стомакот, градите или зглобовите, обично придружена со висока телесна 
температура. Таа класично се наследува автосомно рецесивно и еповрзана со мутации на MEFV генот, кој го кодира 
протеинот пирин. До сега, повеќе од 140 мутации во MEFVгенотсе дефинирани во светот. И покрај напредокот,во 
технологијата и воведувањетона тестови практични за рутинска употреба, околу 20% од пациентите со ФМФ 
остануваат без откриена мутација во MEFVгенот. Ова е главната причина зошто дијагнозата на ФМФ останува 
уште клиничка, според TelHashomerкритериумите. Десет годишно девојче е примено на Клиниката за педијатрија 
на Медицинскиот факултет во Скопје заради необјаснива треска. Бројни лабораториски анализи и специјалистички 
консултации беа направени и поради недостаток на објаснение за треската,побарано е генетско тестирање за ФМФ. 
Присуството на хетерозиготна E148Q мутација беше потврдено на Институтот за Имунобиологија и хумана генетика 
со користење на методот реверзнахибридизација.   Терапијата со колхицин, лек на избор, во доза од 1,5 mg/ден, 
доведе до потполно повлекување на симптомите по само неколку дена. 
Иако болеста  класично се наследува по рецесивен начин, опишани се некои атипични случаи на автозомно 
доминантно наследување. Нашиот пациент може да биде уште еден случај за поддршка на овој необичен начин на 
доминантно наследување, бидејќи  хетерозиготната мутација E148Q е единствениот позитивен наод во генотипизација 
на 12 најчести MEFV мутации.
